American higher education has been grappling with both sides of the ROI equation — tuition costs and graduate earnings. It’s ...
54mon MSNOpinion
Contributor: By loosening standards, the FDA isn't doing rare-disease patients any favors
It's reasonable to assess rare-disease drugs differently. That's why the FDA has been remarkably flexible about these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback